PharmaGems, which launched earlier this year to partner entrepreneurial individuals and businesses in the healthcare market research space, today announced the addition of Allan Bowditch and Kathryn Jones to the PharmaGems team.
Bowditch – who also becomes a shareholder – will join the PharmaGems Board, while Jones will become Advisor to the Board. The newly strengthened Board, a think tank of industry heavyweights, will continue to channel research, business and financial expertise into the growth and development of entrepreneurial individuals and businesses.
Bowditch is a highly regarded figure in the healthcare market research industry. During an extensive market research career that includes both client-side and agency roles, he has developed a range of innovative healthcare MR approaches.
In addition, he has worked with the Market Research Society (MRS) to develop the curriculum for the new Market Research degree being run in conjunction with UK Universities, assisted the University of Georgia in adapting the ‘Principles of Market Research’ for Healthcare, and played an instrumental role in developing the EphMRA Guidelines on Adverse Event Reporting.
Bowditch’s service to the industry has been recognised by an EphMRA Award for Contribution to Pharmaceutical Market Research (2002), a PBIRG Lifetime Achievement Award (2005) and numerous awards for best conference paper.
Formerly CEO and Chairman of the Healthcare Division at GfK Martin Hamblin, Bowditch now runs his own healthcare MR consultancy business.
“Everyone, no matter how senior, needs guidance and support to optimise what they are striving to achieve in business; no-one can successfully remain an island. PharmaGems, with its seniority and diversified background, acts a true catalyst for entrepreneurs in our industry and I’m delighted to be a part of that!”
Jones also brings a wealth of additional expertise to the PharmaGems team. With a 20- year healthcare market research career spanning both client- and agency-side, Europe and Stateside, Jones has held senior positions with major names such as Wyeth, Zeneca Pharmaceuticals, IMS Health, Isis and Martin Hamblin.
Also a major contributor to the industry, Jones is a past President of PBIRG, has served on BPMRG's Executive Committees and provides market research consulting services including commercial workshops for market analysts and cross functional drug development teams.
A regular speaker at industry conferences, Jones was recently short-listed for best paper at the EphMRA Annual Conference 2010. She is now President of her own consulting company, Kariad Partners.
“I’ve always been passionate about innovation and entrepreneurialism in
healthcare market research, and so the PharmaGems vision is very close to my heart. I’m really excited about working with the Board to support individuals and businesses and, by extension, the industry.”
Added Pharmagems’ Co-Founder, Peter Chopra:
“We’re delighted to welcome Allan and Kathryn on board. Their unparalleled knowledge and experience truly extends the range of services PharmaGems can offer.
Fellow Co-Founder, Michael Spedding, agreed:
“This is an important development for both PharmaGems and our entrepreneurial partners.”
London - 16 August 2010